NASDAQ:CDLXCardlytics Stock Price, Forecast & News

Cardlytics' stock was trading at $45.83 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CDLX stock has increased by 48.3% and is now trading at $67.96.
View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Cardlytics.

Cardlytics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Cardlytics.

Cardlytics Inc (NASDAQ:CDLX) released its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.38) EPS for the quarter, beating the Zacks' consensus estimate of ($0.74) by $0.36. The company earned $28.22 million during the quarter, compared to analysts' expectations of $30.84 million. Cardlytics had a negative net margin of 18.86% and a negative return on equity of 26.14%. The firm's quarterly revenue was down 42.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.12) earnings per share.
View Cardlytics' earnings history.

6 analysts have issued 12 month target prices for Cardlytics' stock. Their forecasts range from $26.00 to $75.00. On average, they expect Cardlytics' share price to reach $55.17 in the next year. This suggests that the stock has a possible downside of 18.8%.
View analysts' price targets for Cardlytics.

Media coverage about CDLX stock has trended negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cardlytics earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Cardlytics.

Some companies that are related to Cardlytics include Legend Biotech (DADA), HUYA (HUYA), DouYu International (DOYU), Switch (SWCH), Medallia (MDLA), SVMK (SVMK), Pluralsight (PS), Tripadvisor (TRIP), 21Vianet Group (VNET), Sabre (SABR), Internet Initiative Japan (IIJIY), Model N (MODN), Health Catalyst (HCAT), Qutoutiao (QTT) and Eventbrite (EB).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include Alibaba Group (BABA), Trade Desk (TTD), Advanced Micro Devices (AMD), NVIDIA (NVDA), Caterpillar (CAT), Roku (ROKU), Micron Technology (MU), Netflix (NFLX), Square (SQ) and Walt Disney (DIS).

(CDLX) raised $76 million in an IPO on Friday, February 9th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

Cardlytics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Frontier Capital Management Co. LLC (1.67%), Jennison Associates LLC (1.63%), Ziegler Capital Management LLC (0.34%), First Trust Advisors LP (0.27%), Serengeti Asset Management LP (0.26%) and Tygh Capital Management Inc. (0.26%). Company insiders that own Cardlytics stock include Aimia Inc, Andrew Christiansen, Bryce Youngren, Clifford Sosin, David Leslie Adams, David Thomas Evans, John L Jr Klinck, John V Balen, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Polaris Venture Management Co, Scott D Grimes and Tony Weisman.
View institutional ownership trends for Cardlytics.

CDLX stock was sold by a variety of institutional investors in the last quarter, including RMB Capital Management LLC, Frontier Capital Management Co. LLC, Hancock Whitney Corp, Hussman Strategic Advisors Inc., Jennison Associates LLC, and Brave Asset Management Inc.. Company insiders that have sold Cardlytics company stock in the last year include Aimia Inc, Andrew Christiansen, Bryce Youngren, David Leslie Adams, David Thomas Evans, John L Jr Klinck, Kirk Somers, Lynne Marie Laube, Mark A Johnson, Scott D Grimes, and Tony Weisman.
View insider buying and selling activity for Cardlytics.

CDLX stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Serengeti Asset Management LP, Tygh Capital Management Inc., Ziegler Capital Management LLC, Roubaix Capital LLC, Calamos Advisors LLC, Russell Investments Group Ltd., and Columbus Circle Investors. Company insiders that have bought Cardlytics stock in the last two years include Clifford Sosin, and John V Balen.
View insider buying and selling activity for Cardlytics.

Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CDLX stock can currently be purchased for approximately $67.96.

Cardlytics has a market capitalization of $1.83 billion and generates $210.43 million in revenue each year. The company earns $-17,140,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

The official website for Cardlytics is www.cardlytics.com.

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at 888-798-5802 or via email at [email protected]